APMA study materials
APMA study resources

The Growth Manager Who Beat the Benchmark by Taking More Risk

APMA · Put your knowledge to work in context.

All case studies

The Growth Manager Who Beat the Benchmark by Taking More Risk

A large-cap growth manager returned 18.2% over three years versus a benchmark return of 15.1%. The plan sponsor's consultant reports: beta 1.18, standard deviation of excess returns (tracking error) 6.4%, information ratio 0.48, and a Sharpe ratio of 0.71 versus the benchmark's 0.68. The manager's top-10 holdings are 48% of the portfolio versus 31% for the benchmark, and the portfolio holds 42 names versus 520 in the index. Over the same period the growth style index returned 16.9%. The consultant must decide whether to recommend the manager's retention, and the sponsor has a policy that active managers must add value on a risk-adjusted basis, not just raw return.

1. Decompose the manager's 3.1% annualized outperformance. How much is attributable to beta, how much to style, and how much to genuine selection?

Read the worked answer

Rough decomposition (annualized, over the 3-year period):

  1. Beta contribution: beta 1.18 vs 1.00 means the manager took 18% more market risk. If the market returned, say, ~13% annualized, the beta-driven excess is roughly (1.18 − 1.00) × 13% ≈ 2.3%. That is the largest single piece of the 3.1%.
  2. Style contribution: the growth style index beat the broad benchmark by 16.9% − 15.1% = 1.8%. A manager with a growth tilt would capture much of this simply by being in the style. If the manager's style exposure explains, say, half to all of that, style accounts for roughly 0.9–1.8%.
  3. Selection (residual): 3.1% − 2.3% (beta) − ~1.4% (style, midpoint) ≈ −0.6%, i.e., selection may have been negative once beta and style are removed.

The numbers do not add to a clean positive alpha; they suggest the outperformance is substantially explained by higher market exposure and a growth tailwind. That is exactly what the sponsor's policy is designed to catch. Note: the IR of 0.48 is modest (below ~0.5 is generally unimpressive), and the Sharpe advantage (0.71 vs 0.68) is thin and partly a consequence of the higher-beta regime, not skill.

2. The manager argues the high active share (42 names, top-10 at 48%) is evidence of skill and that tracking error of 6.4% is appropriate for a high-conviction growth mandate. How should the consultant weigh this against the sponsor's risk-adjusted-value policy?

Read the worked answer

Active share and concentration are inputs to a skill story, not evidence of it. High active share with a positive information ratio is consistent with skill; high active share with an IR of 0.48 and a beta-driven return pattern is consistent with a leveraged bet on growth and market risk. The consultant should separate the two claims:

  • Concentration is not the problem per se. 42 names and 48% top-10 is a legitimate high-conviction style. The mandate should state the expected tracking-error budget; 6.4% is high but within a reasonable range for a high-conviction growth sleeve if the sponsor sized the allocation accordingly (e.g., a 10% sleeve with 6.4% TE contributes ~0.64% to total plan TE - acceptable).
  • The problem is the return attribution. The sponsor's policy requires risk-adjusted value-add. On the evidence, the manager's excess return is largely beta and style, and the IR is weak. The manager has not demonstrated alpha; the manager has demonstrated a more aggressive implementation of growth.
  • The right question is whether the sponsor wants a high-beta growth exposure. If yes, the manager is a fine implementation but should be judged against a growth benchmark with a beta-adjusted lens, and the fee should reflect that the sponsor is buying beta + style, not alpha. If the sponsor wants alpha, this manager has not delivered it.

Recommendation: retain only if the sponsor explicitly wants the growth/beta exposure and renegotiates the mandate to a style-consistent benchmark (the growth index) with a beta-adjusted evaluation. If the policy is strict about risk-adjusted alpha, the evidence supports a watch or termination, not retention on the raw 3.1%.